Johnson & Johnson (NYSE:JNJ) Position Trimmed by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 35,896 shares of the company’s stock after selling 1,074 shares during the period. Geneos Wealth Management Inc.’s holdings in Johnson & Johnson were worth $5,626,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Impax Asset Management Group plc boosted its stake in Johnson & Johnson by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 86,904 shares of the company’s stock worth $13,621,000 after purchasing an additional 6,209 shares during the period. Stiles Financial Services Inc boosted its stake in Johnson & Johnson by 2.1% in the 4th quarter. Stiles Financial Services Inc now owns 18,111 shares of the company’s stock worth $2,840,000 after purchasing an additional 376 shares during the period. Keener Financial Planning LLC acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $40,000. Harbour Trust & Investment Management Co acquired a new position in Johnson & Johnson in the 4th quarter worth approximately $8,774,000. Finally, Hemington Wealth Management boosted its stake in Johnson & Johnson by 3.4% in the 4th quarter. Hemington Wealth Management now owns 18,384 shares of the company’s stock worth $2,882,000 after purchasing an additional 609 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0 %

Johnson & Johnson stock opened at $147.49 on Tuesday. The company has a market capitalization of $355.42 billion, a P/E ratio of 10.68, a P/E/G ratio of 2.48 and a beta of 0.53. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm’s fifty day simple moving average is $157.07 and its 200-day simple moving average is $155.90.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Raymond James increased their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley cut their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.